ライフサイエンスコーパス: goserelin

1 g daily 21 days after the first injection of goserelin.

2 tumor flare (16% v 3%) were more common with goserelin.

3 ents received combined ADT that consisted of goserelin 3.6 mg every 4 weeks and flutamide 250 mg tid

4 Patients were treated with goserelin 3.6 mg subcutaneous monthly and began anastroz

5 esia 5 weeks after endometrial thinning with goserelin 3.6 mg.

6 Patients were randomly assigned to goserelin (3.6 mg subcutaneously every 4 weeks; (n = 69)

7 immediate antiandrogen therapy, with either goserelin, a synthetic agonist of gonadotropin-releasing

8 d 198 healthy men 20 to 50 years of age with goserelin acetate (to suppress endogenous testosterone a

9 After chemotherapy, goserelin acetate and bicalutamide were prescribed for 1

10 2b-T4 prostate cancer received flutamide and goserelin acetate for 4 months, with RT beginning at the

11 Another 202 healthy men received goserelin acetate, placebo gel or testosterone gel, and

12 nety-eight healthy men, ages 20-50, received goserelin acetate, which suppresses endogenous gonadal s

13 djuvant endocrine therapy, she began monthly goserelin administration to achieve ovarian function sup

14 rial of men treated with or without adjuvant goserelin after radiation therapy (RT) for locally advan

15 ADT consisted of goserelin and bicalutamide for 2 years.

16 AF-Z), or CAF followed by 5 years of monthly goserelin and daily tamoxifen (CAF-ZT).

17 After two monthly treatments with goserelin and exemestane, a sensitive assay for serum es

18 All patients received 4 months of goserelin and flutamide before and during RT.

19 ion changes after 3 months of treatment with goserelin and flutamide.

20 Goserelin and ovariectomy resulted in similar FFS and OS

21 FFS and OS were similar for goserelin and ovariectomy.

22 served as controls and received placebos for goserelin and testosterone.

23 at 5 years, 84% of patients on the adjuvant goserelin arm and 71% on the observation arm remain with

24 r disease-free survival rate on the adjuvant goserelin arm is 53% versus 20% on the observation arm (

25 tuarial 5-year survival (66% on the adjuvant goserelin arm v 55% on the observation arm) reaches stat

26 il (CAF), CAF followed by 5 years of monthly goserelin (CAF-Z), or CAF followed by 5 years of monthly

27 elin group) or standard chemotherapy without goserelin (chemotherapy-alone group).

28 ally localized PCa were randomly assigned to goserelin combined with dutasteride (ZD), bicalutamide a

29 that treatment of prostate cancer cells with goserelin-conjugated gold nanorods (gGNRs) promotes gona

30 Participants were randomized to active (goserelin [GnRHa] 3.6 mg implant) or placebo interventio

31 standard chemotherapy with the GnRH agonist goserelin (goserelin group) or standard chemotherapy wit

32 .4% v 11.4% for men treated without adjuvant goserelin (Gray's P = .17).

33 ne group (21% vs. 11%, P=0.03); women in the goserelin group also had improved disease-free survival

34 data, the ovarian failure rate was 8% in the goserelin group and 22% in the chemotherapy-alone group

35 ted, pregnancy occurred in more women in the goserelin group than in the chemotherapy-alone group (21

36 hemotherapy with the GnRH agonist goserelin (goserelin group) or standard chemotherapy without gosere

37 ratio, 1.1315 [CI, 0.533 to 2.404]) than for goserelin (hazard ratio, 1.1172 [CI, 0.898 to 1.390]).

38 ted a randomized phase III trial of adjuvant goserelin in definitively irradiated patients with carci

39 (short-term ADT [STAD] + RT) or 24 months of goserelin (long-term ADT [LTAD] + RT).

40 Goserelin lowered serum estradiol to postmenopausal leve

41 erapy (short-term [ST]AD-RT) or 24 months of goserelin (LTAD-RT); 1,554 patients were entered onto th

42 er were randomly assigned to RT and adjuvant goserelin or RT alone.

43 The goserelin/ovariectomy death hazards ratio was .80 and th

44 The combination of goserelin plus anastrozole has substantial antitumor act

45 ; P = .16; when censoring at time of salvage goserelin therapy, HR = 0.99; 95% CI, 0.58 to 1.69; P =

46 ere was no overall advantage for addition of goserelin to CAF.

47 es (GnRHa; nafarelin, leuprolide, buserelin, goserelin, triptorelin), laparoscopic ablation, and exci

48 ascular mortality for men receiving adjuvant goserelin was 8.4% v 11.4% for men treated without adjuv

49 Goserelin was safe and well tolerated.

50 pretation of the findings, administration of goserelin with chemotherapy appeared to protect against